TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
29.315 USD
+0.76 (+2.64%)
ChartMill assigns a Buy % Consensus number of 83% to TEVA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.07. This target is -99.77% below the current price.
TEVA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TEVA.
In the last month the buy percentage rose by 41 points. So the trust of analysts is improving.
TEVA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-08 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-05 | ScotiaBank | Initiate | Sector Outperform |
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-24 | UBS | Maintains | Buy -> Buy |
| 2025-06-26 | UBS | Maintains | Buy -> Buy |
| 2025-06-06 | Goldman Sachs | Initiate | Buy |
| 2025-05-28 | Truist Securities | Initiate | Buy |
| 2025-05-12 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-05-08 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-30 | UBS | Maintains | Buy -> Buy |
| 2025-01-30 | Barclays | Maintains | Overweight -> Overweight |
| 2025-01-23 | UBS | Maintains | Buy -> Buy |
| 2025-01-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-18 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-23 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-21 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-09-03 | UBS | Maintains | Buy -> Buy |
| 2024-08-01 | Barclays | Maintains | Overweight -> Overweight |
| 2024-07-10 | UBS | Maintains | Buy -> Buy |
| 2024-06-27 | Jefferies | Maintains | Buy -> Buy |
| 2024-06-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-30 | B of A Securities | Maintains | Buy -> Buy |
| 2024-05-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2024-03-08 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-12 | Piper Sandler | Upgrade | Neutral -> Overweight |
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the price target for TEVA stock?
7 analysts have analysed TEVA and the average price target is 0.07 USD. This implies a price decrease of -99.77% is expected in the next year compared to the current price of 29.315.
Can you provide the consensus rating for TEVA PHARMACEUTICAL-SP ADR stock?
The consensus rating for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The number of analysts covering TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.